Advertisement
Approximately 10 million people in the U.S. are allergic to cat dander,the most common pet allergy. Cat allergies are about twice as common as dogallergies. Each year, allergies account for more than 17 million outpatientoffice visits in the United States. The annual cost of allergies is estimatedto be nearly $7 billion. Allergy is the 5th leading chronic disease in theU.S. among all ages, and the 3rd most common chronic disease among childrenunder 18 years old.
Advertisement
"Consumers will now be able to screen for allergies to cats in the privacyof their own home. The CE regulatory approval allows us to sell our product todrugstores and other retailers throughout Europe," said Zackary Irani, CEO ofBiomerica. "We are entering into discussions with several distributors invarious European countries."
Biomerica's Fortel Cat allergy test utilizes an advanced technology thatrequires only a drop of a person's blood with results in 15 minutes. TheFortel(R) Cat Allergy Test is a part of Biomerica's line of easy to use testsdesigned to detect diseases before they become catastrophic, incurable orcostly to treat.
About Biomerica (OTC Bulletin Board: BMRA)
Biomerica, Inc. (http://www.biomerica.com) is a global medical technologycompany, based in Newport Beach, CA. The Company manufactures and marketsadvanced diagnostic products used at home, in hospitals, and in physicians'offices for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a "safeharbor" for forward-looking statements. Certain information included in thispress release (as well as information included in oral statements or otherwritten statements made or to be made by Biomerica) contains statements thatare forward-looking; such as statements relating to intended launch dates,sales potential, significant benefits, market size, growth of business,favorable positions, expansion, expected orders, leading market positions,anticipated future revenues or production volume of the Company, success ofproduct and new product offerings. Such forward-looking information involvesimportant risks and uncertainties that could significantly affect anticipatedresults in the future, and accordingly, such results may differ materiallyfrom those expressed in any forward-looking statements made by or on behalf ofBiomerica. The potential risks and uncertainties include, among others,fluctuations in the Company's operating results due to its business model andexpansion plans, downturns in international and or national economies, theCompany's ability to raise additional capital, the competitive environment inwhich the Company will be competing, and the Company's dependence on strategicrelationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
SOURCE Biomerica, Inc.
